Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

264.96
+3.131.20%
Post-market: 266.401.44+0.54%19:59 EDT
Volume:5.16M
Turnover:1.37B
Market Cap:468.29B
PE:74.85
High:266.84
Open:260.70
Low:260.10
Close:261.83
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.05
T/O Rate:0.29%
Dividend:6.83
Dividend Rate:2.58%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-78.90
PE(LYR):112.27

Loading ...

Basilea Publishes Investor Presentation on Anti-Infectives Strategy and Pipeline Progress

Reuters
·
Aug 18

AbbVie is Maintained at Overweight by Wells Fargo

Dow Jones
·
Aug 17

Abbvie, Inc. : Wells Fargo Raises Target Price to $300 from $295

THOMSON REUTERS
·
Aug 17

Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating

MT Newswires Live
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

AbbVie Steps Deeper Into Alzheimer’s: What the ABBV-1758 Trial Means for Investors

TIPRANKS
·
Aug 15

AbbVie Wraps Real‑World China Study on Upadacitinib in Atopic Dermatitis: What Investors Should Watch

TIPRANKS
·
Aug 15

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)

TIPRANKS
·
Aug 13

Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300

MT Newswires Live
·
Aug 13

What Is AbbVie (ABBV) Poised To Gain From FDA Review Of New BOTOX Use?

Simply Wall St.
·
Aug 12

Apogee Shareholders Approve AbbVie Acquisition and Leadership Transition

TIPRANKS
·
Aug 12

Apogee Therapeutics Gelar Rapat Khusus Pemegang Saham Lewat Webcast Langsung

Reuters
·
Aug 12

AbbVie Price Target Raised to $247.00/Share from $218.00 by BNP Paribas

Dow Jones
·
Aug 12

AbbVie Targets Key Lung Cancer Market With New Phase 3 ABBV-1480 Trial

TIPRANKS
·
Aug 12

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 11

Abbvie : BNP Paribas Raises Target Price to $247 from $218

THOMSON REUTERS
·
Aug 11

BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating

MT Newswires Live
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11

Enanta Pharmaceuticals Q3 Revenue Misses Estimates, Hurt by Lower Royalties

Reuters
·
Aug 11

Enanta FY26 Q3 Net Loss Widens to $19.5 Million; Revenue Falls to $14.4 Million

Reuters
·
Aug 11